FORM 4

(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average bu	rden					
hours per response	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * DHILLON PUNIT					2. Issuer Name and Ticker or Trading Symbol Emerald Bioscience, Inc. [EMBI]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)X Director 10% Owner					
(Last) 5910 PAC	IFIC CEN	3. Date of Earliest Transaction (Month/Day/Year) 08/07-05:00/2020								X Officer (give title below) Other (specify below) CEO							
(Street) SAN DIEGO, CA 92121				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)		(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)					, if Code (Inst	(Instr. 8)		4. Securities Acquired (A) Disposed of (D) (Instr. 3, 4 and 5)		` ′	Owned Following Reported Ov Transaction(s) Fo		Ownership form:	Beneficial			
				(Month/	/Day/Ye		ode	V	Amount	(A) or (D)	Price	(Instr. 3 and 4) Direct (D) or Indirect (I) (Instr. 4)			r Indirect (Ownership Instr. 4)	
Common S	Stock		08/07- 05:00/2020]	P		1,000,00	0 A	\$ 100,000	1,000,000		I)		
Reminder: Re	eport on a sep	parate line for each c						Per this cur	sons who form are rently val	not req d OMB					SEC 1	474 (9-02)	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (e.g., puts, calls, warrants, control of the Execution Date, if Transaction Derivative (e.g., puts, calls, warrants, control of the Execution Date, if Transaction Derivative (e.g., puts, calls, warrants, control of the Execution Date, if Transaction Derivative (e.g., puts, calls, warrants, control of the Execution Date)		6. Dat Expira	Expiration Date Under			erlying Securities r. 3 and 4) Deriv Securities (Instruction)		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownersl Form of Derivati Security Direct (I or Indire	Ownership (Instr. 4)					
				Code	V	(A)	(D)	Date Exerci	Exp Date	iration e	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)		
Employee Option Grant (Right to Buy)	\$ 0.045	08/07- 05:00/2020		A	9,	000,000		(<u>2)</u> "	08/07- 00/2030	Commo Stock	9,000,000	\$ 0	9,200,000	D		

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
DHILLON PUNIT 5910 PACIFIC CENTER BLVD SUITE 320 SAN DIEGO, CA 92121	X		CEO			

Signatures

/s/Punit Dhillon	08/11-05:00/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Private purchase transaction from Emerald Health Sciences at \$0.10 per share.
- (2) Each of the Options shall be exercisable for a price of \$0.045 per Option Share for ten years from August 7, 2020 (the "Grant Date") and all Options will vest 10% on the Grant Date and 90% in equal semiannual installments over four and a half years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.